| 1 | unpublished | 2,223 |
| 2 | quasi-randomised | 1,369 |
| 3 | quasi-randomized | 590 |
| 4 | vice | 465 |
| 5 | inter-day | 145 |
| 6 | quasi-random | 84 |
| 7 | interday | 47 |
| 8 | inter-assay | 43 |
| 9 | 'randomized | 31 |
| 10 | diamicron | 28 |
| 11 | pseudo-randomised | 20 |
| 12 | quasirandomized | 15 |
| 13 | wheez* | 15 |
| 14 | 'controlled | 13 |
| 15 | pseudorandomized | 12 |
| 16 | diamicron-mr | 11 |
| 17 | 'randomised | 10 |
| 18 | inter-batch | 10 |
| 19 | quasirandomised | 9 |
| 20 | benefit-ext | 8 |
| 21 | miracle-icd | 8 |
| 22 | pseudorandomised | 8 |
| 23 | wies | 8 |
| 24 | zero-event | 8 |
| 25 | non-published | 7 |
| 26 | inter-run | 6 |
| 27 | rs1042719 | 6 |
| 28 | salt-2 | 6 |
| 29 | semi-random | 6 |
| 30 | uk-specific | 6 |
| 31 | act-2 | 5 |
| 32 | active-comparator-controlled | 5 |
| 33 | bag-recall | 5 |
| 34 | between-assay | 5 |
| 35 | cf-302 | 5 |
| 36 | mm-010 | 5 |
| 37 | scsocs | 5 |
| 38 | slco1b | 5 |
| 39 | unrewarded | 5 |
| 40 | wollongong | 5 |
| 41 | 6-items | 4 |
| 42 | antimicr* | 4 |
| 43 | bernouilli | 4 |
| 44 | cyp2e1*5 | 4 |
| 45 | d-stat | 4 |
| 46 | high-error | 4 |
| 47 | lytics | 4 |
| 48 | memos | 4 |
| 49 | non-industry-sponsored | 4 |
| 50 | noncued | 4 |
| 51 | nonpublished | 4 |
| 52 | olanzapine-controlled | 4 |
| 53 | paragon-b | 4 |
| 54 | post-ripening | 4 |
| 55 | rossiter | 4 |
| 56 | s-trac | 4 |
| 57 | semi-randomised | 4 |
| 58 | testpert | 4 |
| 59 | trolled | 4 |
| 60 | 'partially | 3 |
| 61 | 60na | 3 |
| 62 | =6-month | 3 |
| 63 | a-care | 3 |
| 64 | adher* | 3 |
| 65 | cbz.eight | 3 |
| 66 | cbz.nine | 3 |
| 67 | db/db-cardiac | 3 |
| 68 | dihydroarte* | 3 |
| 69 | ebpb | 3 |
| 70 | educ* | 3 |
| 71 | epilepsy.for | 3 |
| 72 | establish-2 | 3 |
| 73 | interlingual | 3 |
| 74 | mybiosource | 3 |
| 75 | myracrodruon | 3 |
| 76 | no16967 | 3 |
| 77 | non-available | 3 |
| 78 | non-eerw | 3 |
| 79 | nonenglish | 3 |
| 80 | nonproducer | 3 |
| 81 | ongoing/unpublished | 3 |
| 82 | oz/z | 3 |
| 83 | parameters.three | 3 |
| 84 | participant-blind | 3 |
| 85 | pb/cd | 3 |
| 86 | pglyrp4 | 3 |
| 87 | preventive/treatment | 3 |
| 88 | punishment-based | 3 |
| 89 | reported.three | 3 |
| 90 | rp3 | 3 |
| 91 | sasp-controlled | 3 |
| 92 | sham-injection | 3 |
| 93 | soft-start | 3 |
| 94 | trials.four | 3 |
| 95 | uc- | 3 |
| 96 | urinary/faecal | 3 |
| 97 | xaed | 3 |
| 98 | 'incomplete | 2 |
| 99 | 'toxicology | 2 |
| 100 | animal-model | 2 |
| 101 | armyda-3 | 2 |
| 102 | bias-protected | 2 |
| 103 | cah₂ | 2 |
| 104 | ceram.x | 2 |
| 105 | crt-intervention | 2 |
| 106 | crystalloideight | 2 |
| 107 | diseases/symptoms | 2 |
| 108 | edema3-db | 2 |
| 109 | epa-alone | 2 |
| 110 | failure-a | 2 |
| 111 | feno-driven | 2 |
| 112 | gorup | 2 |
| 113 | group.eleven | 2 |
| 114 | group.four | 2 |
| 115 | groups.six | 2 |
| 116 | hspb4-hspb5 | 2 |
| 117 | in-progress | 2 |
| 118 | infotrieve | 2 |
| 119 | interrupted-time-series | 2 |
| 120 | kampo-related | 2 |
| 121 | low-error | 2 |
| 122 | mp865 | 2 |
| 123 | ni/eq | 2 |
| 124 | no-reward | 2 |
| 125 | non-disposable | 2 |
| 126 | non-truncated | 2 |
| 127 | nonharmonic | 2 |
| 128 | other-language | 2 |
| 129 | oxycodone-hcl | 2 |
| 130 | parental- | 2 |
| 131 | population.no | 2 |
| 132 | publicly-sponsored | 2 |
| 133 | quazi-randomized | 2 |
| 134 | radionuclidic | 2 |
| 135 | rational-designed | 2 |
| 136 | single-season | 2 |
| 137 | thop | 2 |
| 138 | train* | 2 |
| 139 | triad-vlc | 2 |
| 140 | unpublished/ongoing | 2 |
| 141 | upar-binding | 2 |
| 142 | verum-controlled | 2 |
| 143 | zo-fast | 2 |
| 144 | β2ar46 | 2 |
| 145 | 'absorption | 1 |
| 146 | 'arte* | 1 |
| 147 | 'carrots | 1 |
| 148 | 'edoxaban | 1 |
| 149 | 'miscellaneous | 1 |
| 150 | 'occurrence | 1 |
| 151 | 'quasi-randomised | 1 |
| 152 | -2002p | 1 |
| 153 | -2005 | 1 |
| 154 | -ads | 1 |
| 155 | -conducted | 1 |
| 156 | -fortification | 1 |
| 157 | -performed | 1 |
| 158 | -randomised | 1 |
| 159 | -traits | 1 |
| 160 | 0.29,0.13-0.67 | 1 |
| 161 | 1'-azido-2',3',5'-tri-o-benzoylribose | 1 |
| 162 | 1.17-4.08 | 1 |
| 163 | 1.64-2.02 | 1 |
| 164 | 10/mm3 | 1 |
| 165 | 13w6d | 1 |
| 166 | 15'-cis-β-carotene | 1 |
| 167 | 2-cyanothioacetamide | 1 |
| 168 | 3'-mercapto-dideoxynucleotides | 1 |
| 169 | 3,3-dimethyl-2-butanone | 1 |
| 170 | 3-bromochromones | 1 |
| 171 | 3-oxo-3-phenylpropanenitrile | 1 |
| 172 | 39,029 | 1 |
| 173 | 400mg/l | 1 |
| 174 | 48/379 | 1 |
| 175 | 75/90 | 1 |
| 176 | 780m | 1 |
| 177 | 8-hydroxy-2-deoxy-guanosine | 1 |
| 178 | 897,683 | 1 |
| 179 | 9,948 | 1 |
| 180 | =-17.4 | 1 |
| 181 | =3cm | 1 |
| 182 | a-930g | 1 |
| 183 | a1438g | 1 |
| 184 | acenaphthylene-1,2-dione | 1 |
| 185 | acs2 | 1 |
| 186 | acu-point | 1 |
| 187 | acucise® | 1 |
| 188 | aidf193a | 1 |
| 189 | alarm-to-imaging | 1 |
| 190 | aloneboth | 1 |
| 191 | anti-heparanase | 1 |
| 192 | apf+co2 | 1 |
| 193 | arv-eligible | 1 |
| 194 | auto-administration | 1 |
| 195 | aver | 1 |
| 196 | azelastine-controlled | 1 |
| 197 | bandaging.eleven | 1 |
| 198 | bia-2-093 | 1 |
| 199 | buccopharyngeal | 1 |
| 200 | c-37/38 | 1 |
| 201 | c-subtype | 1 |
| 202 | calcium-depleting | 1 |
| 203 | capillary-capillary | 1 |
| 204 | cd4/ccr5 | 1 |
| 205 | cdc25b-ser321d | 1 |
| 206 | challenge-chamber | 1 |
| 207 | chart-extracted | 1 |
| 208 | chirurgic | 1 |
| 209 | choledochostomia | 1 |
| 210 | cimicifuage | 1 |
| 211 | cinnarizine.no | 1 |
| 212 | cisplatin/ifosfamide/etoposide | 1 |
| 213 | closure.two | 1 |
| 214 | co2/o2 | 1 |
| 215 | comparison.two | 1 |
| 216 | complications.one | 1 |
| 217 | component.three | 1 |
| 218 | conclu | 1 |
| 219 | conclusions.all | 1 |
| 220 | ctn002 | 1 |
| 221 | cutin-like | 1 |
| 222 | cytobrush® | 1 |
| 223 | deaths.additional | 1 |
| 224 | desorption/diffusion | 1 |
| 225 | detemir-based | 1 |
| 226 | di-o-caffeoyltartaric | 1 |
| 227 | differences.six | 1 |
| 228 | different-tone | 1 |
| 229 | dominant-negative-pld1 | 1 |
| 230 | dramatic/early | 1 |
| 231 | dsct- | 1 |
| 232 | dual-mechanism | 1 |
| 233 | ectomorphic | 1 |
| 234 | ed2- | 1 |
| 235 | effectiveness-orientated | 1 |
| 236 | egypt.two | 1 |
| 237 | eloreta-identified | 1 |
| 238 | emg-controlled | 1 |
| 239 | eom-c. | 1 |
| 240 | epic3 | 1 |
| 241 | errhine | 1 |
| 242 | euph | 1 |
| 243 | examiner-rated | 1 |
| 244 | f-actin/α-actinin-1 | 1 |
| 245 | failure.randomized | 1 |
| 246 | family-settings | 1 |
| 247 | fcgr2a-h/r | 1 |
| 248 | federal/foundation-funded | 1 |
| 249 | feet.two | 1 |
| 250 | fitkids2 | 1 |
| 251 | fluoxetin* | 1 |
| 252 | food/water | 1 |
| 253 | fps≤2 | 1 |
| 254 | fractures.thirteen | 1 |
| 255 | ginsenine | 1 |
| 256 | giorgio | 1 |
| 257 | gly1055 | 1 |
| 258 | glycan-receptor | 1 |
| 259 | gsm-hd | 1 |
| 260 | haemorrhoids.numerous | 1 |
| 261 | heat-aggravated | 1 |
| 262 | height²/resistance | 1 |
| 263 | hgsl+ | 1 |
| 264 | hospital* | 1 |
| 265 | hspa1b1267 | 1 |
| 266 | human1m-duo | 1 |
| 267 | hydroxyectoine-reduced | 1 |
| 268 | hyperfrontality | 1 |
| 269 | hypomaniaque | 1 |
| 270 | ifn-containing | 1 |
| 271 | il28b-related | 1 |
| 272 | ileocolectomy | 1 |
| 273 | immunonegativity | 1 |
| 274 | imt+sg | 1 |
| 275 | included10 | 1 |
| 276 | incontinence.seven | 1 |
| 277 | india.two | 1 |
| 278 | infection-dic-3 | 1 |
| 279 | inter-reporter | 1 |
| 280 | interviewer-adjusted | 1 |
| 281 | investigator-scored | 1 |
| 282 | ipm-treated | 1 |
| 283 | iron-bearing | 1 |
| 284 | jsdn | 1 |
| 285 | judiciousness | 1 |
| 286 | k2/ki | 1 |
| 287 | kenchuto-based | 1 |
| 288 | l-propionyl-carnitine | 1 |
| 289 | laparoscop* | 1 |
| 290 | large-scales | 1 |
| 291 | lere | 1 |
| 292 | less-than-severe | 1 |
| 293 | less/month | 1 |
| 294 | lh+8 | 1 |
| 295 | liotbu | 1 |
| 296 | lks | 1 |
| 297 | macro-embolisms | 1 |
| 298 | macrophage-based | 1 |
| 299 | magnetoelectrically | 1 |
| 300 | major/two | 1 |
| 301 | manufacturer-initiated | 1 |
| 302 | mastaigia | 1 |
| 303 | melt-mediation | 1 |
| 304 | micro-ethics | 1 |
| 305 | multi-case | 1 |
| 306 | multi-merci | 1 |
| 307 | multidisease | 1 |
| 308 | multiphenotype | 1 |
| 309 | nbss-2 | 1 |
| 310 | neurosis-controlled | 1 |
| 311 | ngaka | 1 |
| 312 | nicotinamide-coenzyme | 1 |
| 313 | no-drip | 1 |
| 314 | no-naltrexone | 1 |
| 315 | no-randomized | 1 |
| 316 | non-atn | 1 |
| 317 | non-contingently | 1 |
| 318 | non-grain | 1 |
| 319 | non-ide | 1 |
| 320 | non-pentecostal | 1 |
| 321 | non-regurgitant | 1 |
| 322 | non-rehabilitation | 1 |
| 323 | nonautologous | 1 |
| 324 | noncited | 1 |
| 325 | nonregistration | 1 |
| 326 | nonvalidating | 1 |
| 327 | norzimeldine | 1 |
| 328 | nucleoside-experienced | 1 |
| 329 | o-bearing | 1 |
| 330 | om-related | 1 |
| 331 | omized | 1 |
| 332 | osteoporosis-randomized | 1 |
| 333 | outcome.out-of-hospital | 1 |
| 334 | oxcarbazepine/carbamazepine | 1 |
| 335 | pain/injury/illness-related | 1 |
| 336 | pc2-like | 1 |
| 337 | pe.small | 1 |
| 338 | pericarditis-related | 1 |
| 339 | persistence/compliance | 1 |
| 340 | pharmacist* | 1 |
| 341 | pharmacointervention | 1 |
| 342 | phimosis-associated | 1 |
| 343 | phosphorus-31-nuclear | 1 |
| 344 | physician/transcription | 1 |
| 345 | place- | 1 |
| 346 | placebo/sulfasalazine-controlled | 1 |
| 347 | plk1/2 | 1 |
| 348 | polyether- | 1 |
| 349 | polyethylenglycol | 1 |
| 350 | poor- | 1 |
| 351 | post-anodal | 1 |
| 352 | post-commercialisation | 1 |
| 353 | pr-cr | 1 |
| 354 | pre-reperfusion-era | 1 |
| 355 | pre-stent-era | 1 |
| 356 | presynthesis | 1 |
| 357 | prime.four | 1 |
| 358 | progesterone-controlled | 1 |
| 359 | protein-poor | 1 |
| 360 | provider-referred | 1 |
| 361 | pseudor | 1 |
| 362 | psychiatricclinical | 1 |
| 363 | pyelo-ureterostomy | 1 |
| 364 | q-randomized | 1 |
| 365 | qausi-randomized | 1 |
| 366 | quasi-controlled | 1 |
| 367 | quasi-randomized-controlled | 1 |
| 368 | quazi-randomised | 1 |
| 369 | rate.no | 1 |
| 370 | reference-oil | 1 |
| 371 | registrative | 1 |
| 372 | replacement-level | 1 |
| 373 | respite* | 1 |
| 374 | responder-enrichment | 1 |
| 375 | rict/rvet | 1 |
| 376 | rigorously-conducted | 1 |
| 377 | risperidone-controlled | 1 |
| 378 | root-reinforcing | 1 |
| 379 | saint-ii | 1 |
| 380 | sales.qualitative | 1 |
| 381 | samm | 1 |
| 382 | saponin-treated | 1 |
| 383 | savvy® | 1 |
| 384 | scarp | 1 |
| 385 | shivering.two | 1 |
| 386 | shurnas | 1 |
| 387 | sign-assigned | 1 |
| 388 | simulat* | 1 |
| 389 | single-sensor | 1 |
| 390 | sjb | 1 |
| 391 | sluc | 1 |
| 392 | small-sample-size | 1 |
| 393 | snps-cdkn2bas | 1 |
| 394 | solvd-prevention | 1 |
| 395 | spatial/context | 1 |
| 396 | sponge- | 1 |
| 397 | sr-led | 1 |
| 398 | stathmin-1 | 1 |
| 399 | stepmother | 1 |
| 400 | study.two | 1 |
| 401 | substandard/counterfeit | 1 |
| 402 | sufh-placebo | 1 |
| 403 | survivor-targeted | 1 |
| 404 | survivors.high-quality | 1 |
| 405 | systematically-allocated | 1 |
| 406 | t66i | 1 |
| 407 | tac-sensitive | 1 |
| 408 | tachycardia.nine | 1 |
| 409 | tacrolimus-resistant | 1 |
| 410 | tacrolimus-sensitive | 1 |
| 411 | tasnrk2.3-gfp | 1 |
| 412 | threat-inducing | 1 |
| 413 | thrombus-mimicking | 1 |
| 414 | ticlopodine | 1 |
| 415 | tmt-left | 1 |
| 416 | tnfα/chx | 1 |
| 417 | transcend-randomized | 1 |
| 418 | treatment.more | 1 |
| 419 | trial.three | 1 |
| 420 | triflylamide | 1 |
| 421 | triptan-controlled | 1 |
| 422 | trisulfated | 1 |
| 423 | ugt1a7*3 | 1 |
| 424 | uk/european | 1 |
| 425 | un-published | 1 |
| 426 | unreviewable | 1 |
| 427 | usda-derived | 1 |
| 428 | vise | 1 |
| 429 | without-robot | 1 |
| 430 | yiddish | 1 |
| 431 | ziprasidone-controlled | 1 |
| 432 | zn2-a4v | 1 |
| 433 | α-actinin-1/-4 | 1 |
| 434 | β-carotene-supplementation | 1 |
| 435 | ν=1/3 | 1 |
| 436 | €5121 | 1 |
| 437 | ≤-1.5 | 1 |
| 438 | ≤10-week | 1 |
| 1 | 'absorption | 1 |
| 2 | 'arte* | 1 |
| 3 | 'carrots | 1 |
| 4 | 'controlled | 13 |
| 5 | 'edoxaban | 1 |
| 6 | 'incomplete | 2 |
| 7 | 'miscellaneous | 1 |
| 8 | 'occurrence | 1 |
| 9 | 'partially | 3 |
| 10 | 'quasi-randomised | 1 |
| 11 | 'randomised | 10 |
| 12 | 'randomized | 31 |
| 13 | 'toxicology | 2 |
| 14 | -2002p | 1 |
| 15 | -2005 | 1 |
| 16 | -ads | 1 |
| 17 | -conducted | 1 |
| 18 | -fortification | 1 |
| 19 | -performed | 1 |
| 20 | -randomised | 1 |
| 21 | -traits | 1 |
| 22 | 0.29,0.13-0.67 | 1 |
| 23 | 1'-azido-2',3',5'-tri-o-benzoylribose | 1 |
| 24 | 1.17-4.08 | 1 |
| 25 | 1.64-2.02 | 1 |
| 26 | 10/mm3 | 1 |
| 27 | 13w6d | 1 |
| 28 | 15'-cis-β-carotene | 1 |
| 29 | 2-cyanothioacetamide | 1 |
| 30 | 3'-mercapto-dideoxynucleotides | 1 |
| 31 | 3,3-dimethyl-2-butanone | 1 |
| 32 | 3-bromochromones | 1 |
| 33 | 3-oxo-3-phenylpropanenitrile | 1 |
| 34 | 39,029 | 1 |
| 35 | 400mg/l | 1 |
| 36 | 48/379 | 1 |
| 37 | 6-items | 4 |
| 38 | 60na | 3 |
| 39 | 75/90 | 1 |
| 40 | 780m | 1 |
| 41 | 8-hydroxy-2-deoxy-guanosine | 1 |
| 42 | 897,683 | 1 |
| 43 | 9,948 | 1 |
| 44 | =-17.4 | 1 |
| 45 | =3cm | 1 |
| 46 | =6-month | 3 |
| 47 | a-930g | 1 |
| 48 | a-care | 3 |
| 49 | a1438g | 1 |
| 50 | acenaphthylene-1,2-dione | 1 |
| 51 | acs2 | 1 |
| 52 | act-2 | 5 |
| 53 | active-comparator-controlled | 5 |
| 54 | acu-point | 1 |
| 55 | acucise® | 1 |
| 56 | adher* | 3 |
| 57 | aidf193a | 1 |
| 58 | alarm-to-imaging | 1 |
| 59 | aloneboth | 1 |
| 60 | animal-model | 2 |
| 61 | anti-heparanase | 1 |
| 62 | antimicr* | 4 |
| 63 | apf+co2 | 1 |
| 64 | armyda-3 | 2 |
| 65 | arv-eligible | 1 |
| 66 | auto-administration | 1 |
| 67 | aver | 1 |
| 68 | azelastine-controlled | 1 |
| 69 | bag-recall | 5 |
| 70 | bandaging.eleven | 1 |
| 71 | benefit-ext | 8 |
| 72 | bernouilli | 4 |
| 73 | between-assay | 5 |
| 74 | bia-2-093 | 1 |
| 75 | bias-protected | 2 |
| 76 | buccopharyngeal | 1 |
| 77 | c-37/38 | 1 |
| 78 | c-subtype | 1 |
| 79 | cah₂ | 2 |
| 80 | calcium-depleting | 1 |
| 81 | capillary-capillary | 1 |
| 82 | cbz.eight | 3 |
| 83 | cbz.nine | 3 |
| 84 | cd4/ccr5 | 1 |
| 85 | cdc25b-ser321d | 1 |
| 86 | ceram.x | 2 |
| 87 | cf-302 | 5 |
| 88 | challenge-chamber | 1 |
| 89 | chart-extracted | 1 |
| 90 | chirurgic | 1 |
| 91 | choledochostomia | 1 |
| 92 | cimicifuage | 1 |
| 93 | cinnarizine.no | 1 |
| 94 | cisplatin/ifosfamide/etoposide | 1 |
| 95 | closure.two | 1 |
| 96 | co2/o2 | 1 |
| 97 | comparison.two | 1 |
| 98 | complications.one | 1 |
| 99 | component.three | 1 |
| 100 | conclu | 1 |
| 101 | conclusions.all | 1 |
| 102 | crt-intervention | 2 |
| 103 | crystalloideight | 2 |
| 104 | ctn002 | 1 |
| 105 | cutin-like | 1 |
| 106 | cyp2e1*5 | 4 |
| 107 | cytobrush® | 1 |
| 108 | d-stat | 4 |
| 109 | db/db-cardiac | 3 |
| 110 | deaths.additional | 1 |
| 111 | desorption/diffusion | 1 |
| 112 | detemir-based | 1 |
| 113 | di-o-caffeoyltartaric | 1 |
| 114 | diamicron | 28 |
| 115 | diamicron-mr | 11 |
| 116 | differences.six | 1 |
| 117 | different-tone | 1 |
| 118 | dihydroarte* | 3 |
| 119 | diseases/symptoms | 2 |
| 120 | dominant-negative-pld1 | 1 |
| 121 | dramatic/early | 1 |
| 122 | dsct- | 1 |
| 123 | dual-mechanism | 1 |
| 124 | ebpb | 3 |
| 125 | ectomorphic | 1 |
| 126 | ed2- | 1 |
| 127 | edema3-db | 2 |
| 128 | educ* | 3 |
| 129 | effectiveness-orientated | 1 |
| 130 | egypt.two | 1 |
| 131 | eloreta-identified | 1 |
| 132 | emg-controlled | 1 |
| 133 | eom-c. | 1 |
| 134 | epa-alone | 2 |
| 135 | epic3 | 1 |
| 136 | epilepsy.for | 3 |
| 137 | errhine | 1 |
| 138 | establish-2 | 3 |
| 139 | euph | 1 |
| 140 | examiner-rated | 1 |
| 141 | f-actin/α-actinin-1 | 1 |
| 142 | failure-a | 2 |
| 143 | failure.randomized | 1 |
| 144 | family-settings | 1 |
| 145 | fcgr2a-h/r | 1 |
| 146 | federal/foundation-funded | 1 |
| 147 | feet.two | 1 |
| 148 | feno-driven | 2 |
| 149 | fitkids2 | 1 |
| 150 | fluoxetin* | 1 |
| 151 | food/water | 1 |
| 152 | fps≤2 | 1 |
| 153 | fractures.thirteen | 1 |
| 154 | ginsenine | 1 |
| 155 | giorgio | 1 |
| 156 | gly1055 | 1 |
| 157 | glycan-receptor | 1 |
| 158 | gorup | 2 |
| 159 | group.eleven | 2 |
| 160 | group.four | 2 |
| 161 | groups.six | 2 |
| 162 | gsm-hd | 1 |
| 163 | haemorrhoids.numerous | 1 |
| 164 | heat-aggravated | 1 |
| 165 | height²/resistance | 1 |
| 166 | hgsl+ | 1 |
| 167 | high-error | 4 |
| 168 | hospital* | 1 |
| 169 | hspa1b1267 | 1 |
| 170 | hspb4-hspb5 | 2 |
| 171 | human1m-duo | 1 |
| 172 | hydroxyectoine-reduced | 1 |
| 173 | hyperfrontality | 1 |
| 174 | hypomaniaque | 1 |
| 175 | ifn-containing | 1 |
| 176 | il28b-related | 1 |
| 177 | ileocolectomy | 1 |
| 178 | immunonegativity | 1 |
| 179 | imt+sg | 1 |
| 180 | in-progress | 2 |
| 181 | included10 | 1 |
| 182 | incontinence.seven | 1 |
| 183 | india.two | 1 |
| 184 | infection-dic-3 | 1 |
| 185 | infotrieve | 2 |
| 186 | inter-assay | 43 |
| 187 | inter-batch | 10 |
| 188 | inter-day | 145 |
| 189 | inter-reporter | 1 |
| 190 | inter-run | 6 |
| 191 | interday | 47 |
| 192 | interlingual | 3 |
| 193 | interrupted-time-series | 2 |
| 194 | interviewer-adjusted | 1 |
| 195 | investigator-scored | 1 |
| 196 | ipm-treated | 1 |
| 197 | iron-bearing | 1 |
| 198 | jsdn | 1 |
| 199 | judiciousness | 1 |
| 200 | k2/ki | 1 |
| 201 | kampo-related | 2 |
| 202 | kenchuto-based | 1 |
| 203 | l-propionyl-carnitine | 1 |
| 204 | laparoscop* | 1 |
| 205 | large-scales | 1 |
| 206 | lere | 1 |
| 207 | less-than-severe | 1 |
| 208 | less/month | 1 |
| 209 | lh+8 | 1 |
| 210 | liotbu | 1 |
| 211 | lks | 1 |
| 212 | low-error | 2 |
| 213 | lytics | 4 |
| 214 | macro-embolisms | 1 |
| 215 | macrophage-based | 1 |
| 216 | magnetoelectrically | 1 |
| 217 | major/two | 1 |
| 218 | manufacturer-initiated | 1 |
| 219 | mastaigia | 1 |
| 220 | melt-mediation | 1 |
| 221 | memos | 4 |
| 222 | micro-ethics | 1 |
| 223 | miracle-icd | 8 |
| 224 | mm-010 | 5 |
| 225 | mp865 | 2 |
| 226 | multi-case | 1 |
| 227 | multi-merci | 1 |
| 228 | multidisease | 1 |
| 229 | multiphenotype | 1 |
| 230 | mybiosource | 3 |
| 231 | myracrodruon | 3 |
| 232 | nbss-2 | 1 |
| 233 | neurosis-controlled | 1 |
| 234 | ngaka | 1 |
| 235 | ni/eq | 2 |
| 236 | nicotinamide-coenzyme | 1 |
| 237 | no-drip | 1 |
| 238 | no-naltrexone | 1 |
| 239 | no-randomized | 1 |
| 240 | no-reward | 2 |
| 241 | no16967 | 3 |
| 242 | non-atn | 1 |
| 243 | non-available | 3 |
| 244 | non-contingently | 1 |
| 245 | non-disposable | 2 |
| 246 | non-eerw | 3 |
| 247 | non-grain | 1 |
| 248 | non-ide | 1 |
| 249 | non-industry-sponsored | 4 |
| 250 | non-pentecostal | 1 |
| 251 | non-published | 7 |
| 252 | non-regurgitant | 1 |
| 253 | non-rehabilitation | 1 |
| 254 | non-truncated | 2 |
| 255 | nonautologous | 1 |
| 256 | noncited | 1 |
| 257 | noncued | 4 |
| 258 | nonenglish | 3 |
| 259 | nonharmonic | 2 |
| 260 | nonproducer | 3 |
| 261 | nonpublished | 4 |
| 262 | nonregistration | 1 |
| 263 | nonvalidating | 1 |
| 264 | norzimeldine | 1 |
| 265 | nucleoside-experienced | 1 |
| 266 | o-bearing | 1 |
| 267 | olanzapine-controlled | 4 |
| 268 | om-related | 1 |
| 269 | omized | 1 |
| 270 | ongoing/unpublished | 3 |
| 271 | osteoporosis-randomized | 1 |
| 272 | other-language | 2 |
| 273 | outcome.out-of-hospital | 1 |
| 274 | oxcarbazepine/carbamazepine | 1 |
| 275 | oxycodone-hcl | 2 |
| 276 | oz/z | 3 |
| 277 | pain/injury/illness-related | 1 |
| 278 | paragon-b | 4 |
| 279 | parameters.three | 3 |
| 280 | parental- | 2 |
| 281 | participant-blind | 3 |
| 282 | pb/cd | 3 |
| 283 | pc2-like | 1 |
| 284 | pe.small | 1 |
| 285 | pericarditis-related | 1 |
| 286 | persistence/compliance | 1 |
| 287 | pglyrp4 | 3 |
| 288 | pharmacist* | 1 |
| 289 | pharmacointervention | 1 |
| 290 | phimosis-associated | 1 |
| 291 | phosphorus-31-nuclear | 1 |
| 292 | physician/transcription | 1 |
| 293 | place- | 1 |
| 294 | placebo/sulfasalazine-controlled | 1 |
| 295 | plk1/2 | 1 |
| 296 | polyether- | 1 |
| 297 | polyethylenglycol | 1 |
| 298 | poor- | 1 |
| 299 | population.no | 2 |
| 300 | post-anodal | 1 |
| 301 | post-commercialisation | 1 |
| 302 | post-ripening | 4 |
| 303 | pr-cr | 1 |
| 304 | pre-reperfusion-era | 1 |
| 305 | pre-stent-era | 1 |
| 306 | presynthesis | 1 |
| 307 | preventive/treatment | 3 |
| 308 | prime.four | 1 |
| 309 | progesterone-controlled | 1 |
| 310 | protein-poor | 1 |
| 311 | provider-referred | 1 |
| 312 | pseudo-randomised | 20 |
| 313 | pseudor | 1 |
| 314 | pseudorandomised | 8 |
| 315 | pseudorandomized | 12 |
| 316 | psychiatricclinical | 1 |
| 317 | publicly-sponsored | 2 |
| 318 | punishment-based | 3 |
| 319 | pyelo-ureterostomy | 1 |
| 320 | q-randomized | 1 |
| 321 | qausi-randomized | 1 |
| 322 | quasi-controlled | 1 |
| 323 | quasi-random | 84 |
| 324 | quasi-randomised | 1,369 |
| 325 | quasi-randomized | 590 |
| 326 | quasi-randomized-controlled | 1 |
| 327 | quasirandomised | 9 |
| 328 | quasirandomized | 15 |
| 329 | quazi-randomised | 1 |
| 330 | quazi-randomized | 2 |
| 331 | radionuclidic | 2 |
| 332 | rate.no | 1 |
| 333 | rational-designed | 2 |
| 334 | reference-oil | 1 |
| 335 | registrative | 1 |
| 336 | replacement-level | 1 |
| 337 | reported.three | 3 |
| 338 | respite* | 1 |
| 339 | responder-enrichment | 1 |
| 340 | rict/rvet | 1 |
| 341 | rigorously-conducted | 1 |
| 342 | risperidone-controlled | 1 |
| 343 | root-reinforcing | 1 |
| 344 | rossiter | 4 |
| 345 | rp3 | 3 |
| 346 | rs1042719 | 6 |
| 347 | s-trac | 4 |
| 348 | saint-ii | 1 |
| 349 | sales.qualitative | 1 |
| 350 | salt-2 | 6 |
| 351 | samm | 1 |
| 352 | saponin-treated | 1 |
| 353 | sasp-controlled | 3 |
| 354 | savvy® | 1 |
| 355 | scarp | 1 |
| 356 | scsocs | 5 |
| 357 | semi-random | 6 |
| 358 | semi-randomised | 4 |
| 359 | sham-injection | 3 |
| 360 | shivering.two | 1 |
| 361 | shurnas | 1 |
| 362 | sign-assigned | 1 |
| 363 | simulat* | 1 |
| 364 | single-season | 2 |
| 365 | single-sensor | 1 |
| 366 | sjb | 1 |
| 367 | slco1b | 5 |
| 368 | sluc | 1 |
| 369 | small-sample-size | 1 |
| 370 | snps-cdkn2bas | 1 |
| 371 | soft-start | 3 |
| 372 | solvd-prevention | 1 |
| 373 | spatial/context | 1 |
| 374 | sponge- | 1 |
| 375 | sr-led | 1 |
| 376 | stathmin-1 | 1 |
| 377 | stepmother | 1 |
| 378 | study.two | 1 |
| 379 | substandard/counterfeit | 1 |
| 380 | sufh-placebo | 1 |
| 381 | survivor-targeted | 1 |
| 382 | survivors.high-quality | 1 |
| 383 | systematically-allocated | 1 |
| 384 | t66i | 1 |
| 385 | tac-sensitive | 1 |
| 386 | tachycardia.nine | 1 |
| 387 | tacrolimus-resistant | 1 |
| 388 | tacrolimus-sensitive | 1 |
| 389 | tasnrk2.3-gfp | 1 |
| 390 | testpert | 4 |
| 391 | thop | 2 |
| 392 | threat-inducing | 1 |
| 393 | thrombus-mimicking | 1 |
| 394 | ticlopodine | 1 |
| 395 | tmt-left | 1 |
| 396 | tnfα/chx | 1 |
| 397 | train* | 2 |
| 398 | transcend-randomized | 1 |
| 399 | treatment.more | 1 |
| 400 | triad-vlc | 2 |
| 401 | trial.three | 1 |
| 402 | trials.four | 3 |
| 403 | triflylamide | 1 |
| 404 | triptan-controlled | 1 |
| 405 | trisulfated | 1 |
| 406 | trolled | 4 |
| 407 | uc- | 3 |
| 408 | ugt1a7*3 | 1 |
| 409 | uk-specific | 6 |
| 410 | uk/european | 1 |
| 411 | un-published | 1 |
| 412 | unpublished | 2,223 |
| 413 | unpublished/ongoing | 2 |
| 414 | unreviewable | 1 |
| 415 | unrewarded | 5 |
| 416 | upar-binding | 2 |
| 417 | urinary/faecal | 3 |
| 418 | usda-derived | 1 |
| 419 | verum-controlled | 2 |
| 420 | vice | 465 |
| 421 | vise | 1 |
| 422 | wheez* | 15 |
| 423 | wies | 8 |
| 424 | without-robot | 1 |
| 425 | wollongong | 5 |
| 426 | xaed | 3 |
| 427 | yiddish | 1 |
| 428 | zero-event | 8 |
| 429 | ziprasidone-controlled | 1 |
| 430 | zn2-a4v | 1 |
| 431 | zo-fast | 2 |
| 432 | α-actinin-1/-4 | 1 |
| 433 | β-carotene-supplementation | 1 |
| 434 | β2ar46 | 2 |
| 435 | ν=1/3 | 1 |
| 436 | €5121 | 1 |
| 437 | ≤-1.5 | 1 |
| 438 | ≤10-week | 1 |
| 1 | educ* | 3 |
| 2 | respite* | 1 |
| 3 | 'arte* | 1 |
| 4 | dihydroarte* | 3 |
| 5 | hospital* | 1 |
| 6 | train* | 2 |
| 7 | fluoxetin* | 1 |
| 8 | laparoscop* | 1 |
| 9 | antimicr* | 4 |
| 10 | adher* | 3 |
| 11 | simulat* | 1 |
| 12 | pharmacist* | 1 |
| 13 | wheez* | 15 |
| 14 | hgsl+ | 1 |
| 15 | ed2- | 1 |
| 16 | uc- | 3 |
| 17 | place- | 1 |
| 18 | sponge- | 1 |
| 19 | parental- | 2 |
| 20 | polyether- | 1 |
| 21 | poor- | 1 |
| 22 | dsct- | 1 |
| 23 | eom-c. | 1 |
| 24 | mm-010 | 5 |
| 25 | included10 | 1 |
| 26 | 75/90 | 1 |
| 27 | stathmin-1 | 1 |
| 28 | f-actin/α-actinin-1 | 1 |
| 29 | €5121 | 1 |
| 30 | dominant-negative-pld1 | 1 |
| 31 | establish-2 | 3 |
| 32 | nbss-2 | 1 |
| 33 | act-2 | 5 |
| 34 | salt-2 | 6 |
| 35 | plk1/2 | 1 |
| 36 | 1.64-2.02 | 1 |
| 37 | ctn002 | 1 |
| 38 | cf-302 | 5 |
| 39 | co2/o2 | 1 |
| 40 | apf+co2 | 1 |
| 41 | acs2 | 1 |
| 42 | fitkids2 | 1 |
| 43 | fps≤2 | 1 |
| 44 | ugt1a7*3 | 1 |
| 45 | armyda-3 | 2 |
| 46 | infection-dic-3 | 1 |
| 47 | ν=1/3 | 1 |
| 48 | 897,683 | 1 |
| 49 | bia-2-093 | 1 |
| 50 | epic3 | 1 |
| 51 | 10/mm3 | 1 |
| 52 | rp3 | 3 |
| 53 | α-actinin-1/-4 | 1 |
| 54 | =-17.4 | 1 |
| 55 | pglyrp4 | 3 |
| 56 | cyp2e1*5 | 4 |
| 57 | ≤-1.5 | 1 |
| 58 | -2005 | 1 |
| 59 | gly1055 | 1 |
| 60 | mp865 | 2 |
| 61 | hspb4-hspb5 | 2 |
| 62 | cd4/ccr5 | 1 |
| 63 | β2ar46 | 2 |
| 64 | 0.29,0.13-0.67 | 1 |
| 65 | hspa1b1267 | 1 |
| 66 | no16967 | 3 |
| 67 | lh+8 | 1 |
| 68 | 1.17-4.08 | 1 |
| 69 | c-37/38 | 1 |
| 70 | 9,948 | 1 |
| 71 | rs1042719 | 6 |
| 72 | 39,029 | 1 |
| 73 | 48/379 | 1 |
| 74 | failure-a | 2 |
| 75 | aidf193a | 1 |
| 76 | mastaigia | 1 |
| 77 | choledochostomia | 1 |
| 78 | ngaka | 1 |
| 79 | 60na | 3 |
| 80 | pre-reperfusion-era | 1 |
| 81 | pre-stent-era | 1 |
| 82 | paragon-b | 4 |
| 83 | slco1b | 5 |
| 84 | edema3-db | 2 |
| 85 | sjb | 1 |
| 86 | ebpb | 3 |
| 87 | db/db-cardiac | 3 |
| 88 | s-trac | 4 |
| 89 | radionuclidic | 2 |
| 90 | uk-specific | 6 |
| 91 | chirurgic | 1 |
| 92 | ectomorphic | 1 |
| 93 | nonharmonic | 2 |
| 94 | di-o-caffeoyltartaric | 1 |
| 95 | triad-vlc | 2 |
| 96 | sluc | 1 |
| 97 | cdc25b-ser321d | 1 |
| 98 | 13w6d | 1 |
| 99 | pb/cd | 3 |
| 100 | miracle-icd | 8 |
| 101 | xaed | 3 |
| 102 | nucleoside-experienced | 1 |
| 103 | hydroxyectoine-reduced | 1 |
| 104 | federal/foundation-funded | 1 |
| 105 | unrewarded | 5 |
| 106 | non-published | 7 |
| 107 | un-published | 1 |
| 108 | nonpublished | 4 |
| 109 | unpublished | 2,223 |
| 110 | ongoing/unpublished | 3 |
| 111 | eloreta-identified | 1 |
| 112 | sr-led | 1 |
| 113 | trolled | 4 |
| 114 | 'controlled | 13 |
| 115 | quasi-randomized-controlled | 1 |
| 116 | olanzapine-controlled | 4 |
| 117 | azelastine-controlled | 1 |
| 118 | placebo/sulfasalazine-controlled | 1 |
| 119 | risperidone-controlled | 1 |
| 120 | ziprasidone-controlled | 1 |
| 121 | progesterone-controlled | 1 |
| 122 | emg-controlled | 1 |
| 123 | quasi-controlled | 1 |
| 124 | verum-controlled | 2 |
| 125 | triptan-controlled | 1 |
| 126 | sasp-controlled | 3 |
| 127 | active-comparator-controlled | 5 |
| 128 | neurosis-controlled | 1 |
| 129 | -performed | 1 |
| 130 | rational-designed | 2 |
| 131 | sign-assigned | 1 |
| 132 | investigator-scored | 1 |
| 133 | publicly-sponsored | 2 |
| 134 | non-industry-sponsored | 4 |
| 135 | provider-referred | 1 |
| 136 | macrophage-based | 1 |
| 137 | kenchuto-based | 1 |
| 138 | detemir-based | 1 |
| 139 | punishment-based | 3 |
| 140 | 'randomised | 10 |
| 141 | -randomised | 1 |
| 142 | semi-randomised | 4 |
| 143 | quasi-randomised | 1,369 |
| 144 | 'quasi-randomised | 1 |
| 145 | quazi-randomised | 1 |
| 146 | pseudo-randomised | 20 |
| 147 | quasirandomised | 9 |
| 148 | pseudorandomised | 8 |
| 149 | non-truncated | 2 |
| 150 | systematically-allocated | 1 |
| 151 | ipm-treated | 1 |
| 152 | saponin-treated | 1 |
| 153 | trisulfated | 1 |
| 154 | phimosis-associated | 1 |
| 155 | manufacturer-initiated | 1 |
| 156 | il28b-related | 1 |
| 157 | om-related | 1 |
| 158 | kampo-related | 2 |
| 159 | pericarditis-related | 1 |
| 160 | pain/injury/illness-related | 1 |
| 161 | examiner-rated | 1 |
| 162 | effectiveness-orientated | 1 |
| 163 | heat-aggravated | 1 |
| 164 | chart-extracted | 1 |
| 165 | bias-protected | 2 |
| 166 | -conducted | 1 |
| 167 | rigorously-conducted | 1 |
| 168 | survivor-targeted | 1 |
| 169 | noncited | 1 |
| 170 | interviewer-adjusted | 1 |
| 171 | noncued | 4 |
| 172 | usda-derived | 1 |
| 173 | omized | 1 |
| 174 | 'randomized | 31 |
| 175 | transcend-randomized | 1 |
| 176 | quasi-randomized | 590 |
| 177 | qausi-randomized | 1 |
| 178 | quazi-randomized | 2 |
| 179 | no-randomized | 1 |
| 180 | q-randomized | 1 |
| 181 | osteoporosis-randomized | 1 |
| 182 | failure.randomized | 1 |
| 183 | quasirandomized | 15 |
| 184 | pseudorandomized | 12 |
| 185 | gsm-hd | 1 |
| 186 | participant-blind | 3 |
| 187 | no-reward | 2 |
| 188 | vice | 465 |
| 189 | persistence/compliance | 1 |
| 190 | height²/resistance | 1 |
| 191 | 'occurrence | 1 |
| 192 | mybiosource | 3 |
| 193 | non-ide | 1 |
| 194 | triflylamide | 1 |
| 195 | 2-cyanothioacetamide | 1 |
| 196 | cisplatin/ifosfamide/etoposide | 1 |
| 197 | reported.three | 3 |
| 198 | trial.three | 1 |
| 199 | parameters.three | 3 |
| 200 | component.three | 1 |
| 201 | cimicifuage | 1 |
| 202 | other-language | 2 |
| 203 | pc2-like | 1 |
| 204 | cutin-like | 1 |
| 205 | non-available | 3 |
| 206 | non-disposable | 2 |
| 207 | unreviewable | 1 |
| 208 | arv-eligible | 1 |
| 209 | 3-oxo-3-phenylpropanenitrile | 1 |
| 210 | nicotinamide-coenzyme | 1 |
| 211 | 15'-cis-β-carotene | 1 |
| 212 | norzimeldine | 1 |
| 213 | ticlopodine | 1 |
| 214 | errhine | 1 |
| 215 | tachycardia.nine | 1 |
| 216 | cbz.nine | 3 |
| 217 | ginsenine | 1 |
| 218 | oxcarbazepine/carbamazepine | 1 |
| 219 | 8-hydroxy-2-deoxy-guanosine | 1 |
| 220 | l-propionyl-carnitine | 1 |
| 221 | complications.one | 1 |
| 222 | acenaphthylene-1,2-dione | 1 |
| 223 | epa-alone | 2 |
| 224 | 3,3-dimethyl-2-butanone | 1 |
| 225 | different-tone | 1 |
| 226 | no-naltrexone | 1 |
| 227 | c-subtype | 1 |
| 228 | multiphenotype | 1 |
| 229 | a-care | 3 |
| 230 | lere | 1 |
| 231 | less-than-severe | 1 |
| 232 | treatment.more | 1 |
| 233 | multi-case | 1 |
| 234 | multidisease | 1 |
| 235 | anti-heparanase | 1 |
| 236 | vise | 1 |
| 237 | 1'-azido-2',3',5'-tri-o-benzoylribose | 1 |
| 238 | 'incomplete | 2 |
| 239 | hypomaniaque | 1 |
| 240 | infotrieve | 2 |
| 241 | registrative | 1 |
| 242 | sales.qualitative | 1 |
| 243 | tac-sensitive | 1 |
| 244 | tacrolimus-sensitive | 1 |
| 245 | small-sample-size | 1 |
| 246 | a-930g | 1 |
| 247 | a1438g | 1 |
| 248 | root-reinforcing | 1 |
| 249 | threat-inducing | 1 |
| 250 | upar-binding | 2 |
| 251 | alarm-to-imaging | 1 |
| 252 | thrombus-mimicking | 1 |
| 253 | post-ripening | 4 |
| 254 | ifn-containing | 1 |
| 255 | unpublished/ongoing | 2 |
| 256 | iron-bearing | 1 |
| 257 | o-bearing | 1 |
| 258 | nonvalidating | 1 |
| 259 | calcium-depleting | 1 |
| 260 | wollongong | 5 |
| 261 | imt+sg | 1 |
| 262 | inter-batch | 10 |
| 263 | euph | 1 |
| 264 | yiddish | 1 |
| 265 | nonenglish | 3 |
| 266 | =6-month | 3 |
| 267 | less/month | 1 |
| 268 | aloneboth | 1 |
| 269 | t66i | 1 |
| 270 | multi-merci | 1 |
| 271 | saint-ii | 1 |
| 272 | k2/ki | 1 |
| 273 | bernouilli | 4 |
| 274 | ≤10-week | 1 |
| 275 | 400mg/l | 1 |
| 276 | urinary/faecal | 3 |
| 277 | psychiatricclinical | 1 |
| 278 | post-anodal | 1 |
| 279 | buccopharyngeal | 1 |
| 280 | deaths.additional | 1 |
| 281 | outcome.out-of-hospital | 1 |
| 282 | non-pentecostal | 1 |
| 283 | interlingual | 3 |
| 284 | oxycodone-hcl | 2 |
| 285 | animal-model | 2 |
| 286 | replacement-level | 1 |
| 287 | reference-oil | 1 |
| 288 | conclusions.all | 1 |
| 289 | bag-recall | 5 |
| 290 | pe.small | 1 |
| 291 | polyethylenglycol | 1 |
| 292 | 780m | 1 |
| 293 | =3cm | 1 |
| 294 | samm | 1 |
| 295 | semi-random | 6 |
| 296 | quasi-random | 84 |
| 297 | dual-mechanism | 1 |
| 298 | 'edoxaban | 1 |
| 299 | uk/european | 1 |
| 300 | jsdn | 1 |
| 301 | fractures.thirteen | 1 |
| 302 | bandaging.eleven | 1 |
| 303 | group.eleven | 2 |
| 304 | incontinence.seven | 1 |
| 305 | feno-driven | 2 |
| 306 | non-grain | 1 |
| 307 | desorption/diffusion | 1 |
| 308 | -fortification | 1 |
| 309 | melt-mediation | 1 |
| 310 | nonregistration | 1 |
| 311 | auto-administration | 1 |
| 312 | post-commercialisation | 1 |
| 313 | non-rehabilitation | 1 |
| 314 | β-carotene-supplementation | 1 |
| 315 | sham-injection | 3 |
| 316 | solvd-prevention | 1 |
| 317 | crt-intervention | 2 |
| 318 | pharmacointervention | 1 |
| 319 | physician/transcription | 1 |
| 320 | 'absorption | 1 |
| 321 | diamicron | 28 |
| 322 | single-season | 2 |
| 323 | myracrodruon | 3 |
| 324 | non-atn | 1 |
| 325 | inter-run | 6 |
| 326 | sufh-placebo | 1 |
| 327 | giorgio | 1 |
| 328 | cinnarizine.no | 1 |
| 329 | rate.no | 1 |
| 330 | population.no | 2 |
| 331 | human1m-duo | 1 |
| 332 | india.two | 1 |
| 333 | closure.two | 1 |
| 334 | shivering.two | 1 |
| 335 | comparison.two | 1 |
| 336 | feet.two | 1 |
| 337 | egypt.two | 1 |
| 338 | study.two | 1 |
| 339 | major/two | 1 |
| 340 | -2002p | 1 |
| 341 | tasnrk2.3-gfp | 1 |
| 342 | no-drip | 1 |
| 343 | thop | 2 |
| 344 | scarp | 1 |
| 345 | gorup | 2 |
| 346 | ni/eq | 2 |
| 347 | fcgr2a-h/r | 1 |
| 348 | phosphorus-31-nuclear | 1 |
| 349 | pr-cr | 1 |
| 350 | challenge-chamber | 1 |
| 351 | nonproducer | 3 |
| 352 | stepmother | 1 |
| 353 | food/water | 1 |
| 354 | rossiter | 4 |
| 355 | inter-reporter | 1 |
| 356 | aver | 1 |
| 357 | diamicron-mr | 11 |
| 358 | pseudor | 1 |
| 359 | epilepsy.for | 3 |
| 360 | protein-poor | 1 |
| 361 | high-error | 4 |
| 362 | low-error | 2 |
| 363 | single-sensor | 1 |
| 364 | glycan-receptor | 1 |
| 365 | prime.four | 1 |
| 366 | group.four | 2 |
| 367 | trials.four | 3 |
| 368 | snps-cdkn2bas | 1 |
| 369 | shurnas | 1 |
| 370 | micro-ethics | 1 |
| 371 | lytics | 4 |
| 372 | scsocs | 5 |
| 373 | -ads | 1 |
| 374 | 3'-mercapto-dideoxynucleotides | 1 |
| 375 | interrupted-time-series | 2 |
| 376 | wies | 8 |
| 377 | large-scales | 1 |
| 378 | 3-bromochromones | 1 |
| 379 | family-settings | 1 |
| 380 | presynthesis | 1 |
| 381 | lks | 1 |
| 382 | 6-items | 4 |
| 383 | diseases/symptoms | 2 |
| 384 | macro-embolisms | 1 |
| 385 | memos | 4 |
| 386 | judiciousness | 1 |
| 387 | in-progress | 2 |
| 388 | -traits | 1 |
| 389 | 'carrots | 1 |
| 390 | 'miscellaneous | 1 |
| 391 | nonautologous | 1 |
| 392 | haemorrhoids.numerous | 1 |
| 393 | d-stat | 4 |
| 394 | rict/rvet | 1 |
| 395 | tmt-left | 1 |
| 396 | cbz.eight | 3 |
| 397 | crystalloideight | 2 |
| 398 | substandard/counterfeit | 1 |
| 399 | non-regurgitant | 1 |
| 400 | tacrolimus-resistant | 1 |
| 401 | responder-enrichment | 1 |
| 402 | preventive/treatment | 3 |
| 403 | zero-event | 8 |
| 404 | acu-point | 1 |
| 405 | without-robot | 1 |
| 406 | soft-start | 3 |
| 407 | testpert | 4 |
| 408 | zo-fast | 2 |
| 409 | benefit-ext | 8 |
| 410 | spatial/context | 1 |
| 411 | liotbu | 1 |
| 412 | conclu | 1 |
| 413 | zn2-a4v | 1 |
| 414 | non-eerw | 3 |
| 415 | ceram.x | 2 |
| 416 | tnfα/chx | 1 |
| 417 | differences.six | 1 |
| 418 | groups.six | 2 |
| 419 | inter-day | 145 |
| 420 | interday | 47 |
| 421 | between-assay | 5 |
| 422 | inter-assay | 43 |
| 423 | 'toxicology | 2 |
| 424 | magnetoelectrically | 1 |
| 425 | 'partially | 3 |
| 426 | dramatic/early | 1 |
| 427 | non-contingently | 1 |
| 428 | ileocolectomy | 1 |
| 429 | pyelo-ureterostomy | 1 |
| 430 | capillary-capillary | 1 |
| 431 | hyperfrontality | 1 |
| 432 | survivors.high-quality | 1 |
| 433 | immunonegativity | 1 |
| 434 | oz/z | 3 |
| 435 | cah₂ | 2 |
| 436 | acucise® | 1 |
| 437 | cytobrush® | 1 |
| 438 | savvy® | 1 |